In vitro characterization of ZK 230211-A type III progesterone receptor antagonist with enhanced antiproliferative properties

Journal of Steroid Biochemistry and Molecular Biology

Volumn 119, Issue 1-2, 2010, Pages 45-55

  Afhüppe, Wiebke ^a   Beekman, Johanna M ^a   Otto, Christiane ^a   Korr, Daniel ^a   Hoffmann, Jens ^a   Fuhrmann, Ulrike ^a   Möller, Carsten ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

C Src kinase interaction; NCoR interaction; Nuclear localization; PR antagonist classification; PRE binding activity; T47D cell cycle regulation

Indexed keywords

11BETA (4 ACETYLPHENYL) 17BETA HYDROXY 17ALPHA (1,1,2,2,2 PENTAFLUOROETHYL)ESTRA 4,9 DIEN 3 ONE; ANDROGEN RECEPTOR; CYCLIN D1; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; NUCLEAR RECEPTOR COREPRESSOR; ONAPRISTONE; PROGESTERONE RECEPTOR; PROMEGESTONE; PROTEIN TYROSINE KINASE;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA BINDING; DRUG MECHANISM; ENZYME ACTIVATION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEAR LOCALIZATION SIGNAL; PROMOTER REGION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL NUCLEUS; CELL PROLIFERATION; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CYTOSTATIC AGENTS; DRUG EVALUATION, PRECLINICAL; EFFICIENCY; ESTRENES; FEMALE; HELA CELLS; HUMANS; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTORS, PROGESTERONE; RESPONSE ELEMENTS; TRANSCRIPTIONAL ACTIVATION;

EID: 76749101084     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.12.011     Document Type: Article

References (46)

1. Graham J.D., and Clarke C.L. Physiological action of progesterone in target tissues. Endocr. Rev. 18 4 (1997) 502-519
2. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., and Evans R.M. The nuclear receptor superfamily: the second decade. Cell 83 6 (1995) 835-839
3. Allan G.F., Leng X., Tsai S.Y., Weigel N.L., Edwards D.P., Tsai M.J., and O'Malley B.W. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J. Biol. Chem. 267 27 (1992) 19513-19520
4. Allan G.F., Lombardi E., Haynes-Johnson D., Palmer S., Kiddoe M., Kraft P., Campen C., Rybczynski P., Combs D.W., and Phillips A. Induction of a novel conformation in the progesterone receptor by ZK299 involves a defined region of the carboxyl-terminal tail. Mol. Endocrinol. 10 10 (1996) 1206-1213
5. Chwalisz K., Brenner R.M., Fuhrmann U.U., Hess-Stumpp H., and Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 65 10-11 (2000) 741-751
6. Musgrove E.A., Hamilton J.A., Lee C.S., Sweeney K.J., Watts C.K., and Sutherland R.L. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell Biol. 13 6 (1993) 3577-3587
7. Michna H., Nishino Y., Neef G., McGuire W.L., and Schneider M.R. Progesterone antagonists: tumor-inhibiting potential and mechanism of action. J. Steroid Biochem. Mol. Biol. 41 3-8 (1992) 339-348
8. Schneider M.R., Michna H., Nishino Y., and el Etreby M.F. Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J. Steroid Biochem. Mol. Biol. 37 6 (1990) 783-787
9. Chwalisz K., Hegele-Hartung C., Fritzemeier K.H., Beier H.M., and Elger W. Inhibition of the estradiol-mediated endometrial gland formation by the antigestagen onapristone in rabbits: relationship to uterine estrogen receptors. Endocrinology 129 1 (1991) 312-322
10. Chwalisz K., Stockemann K., Fritzemeier K.H., and Fuhrmann U. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus. Hum. Reprod. Update 4 5 (1998) 570-583
11. Elger W., Bartley J., Schneider B., Kaufmann G., Schubert G., and Chwalisz K. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 65 10-11 (2000) 713-723
12. Klein-Hitpass L., Cato A.C., Henderson D., and Ryffel G.U. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res. 19 6 (1991) 1227-1234
13. Han S.J., Tsai S.Y., Tsai M.J., and O'Malley B.W. Distinct temporal and spatial activities of RU486 on progesterone receptor function in reproductive organs of ovariectomized mice. Endocrinology 148 5 (2007) 2471-2486
14. Meyer M.E., Pornon A., Ji J.W., Bocquel M.T., Chambon P., and Gronemeyer H. Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J. 9 12 (1990) 3923-3932
15. Fuhrmann U., Krattenmacher R., Slater E.P., and Fritzemeier K.H. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 54 4 (1996) 243-251
16. Fuhrmann U., Bengtson C., Repenthin G., and Schillinger E. Stable transfection of androgen receptor and MMTV-CAT into mammalian cells: inhibition of cat expression by anti-androgens. J. Steroid Biochem. Mol. Biol. 42 8 (1992) 787-793
17. Fuhrmann U., Hess-Stumpp H., Cleve A., Neef G., Schwede W., Hoffmann J., Fritzemeier K.H., and Chwalisz K. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J. Med. Chem. 43 26 (2000) 5010-5016
18. Takimoto G.S., Tasset D.M., Eppert A.C., and Horwitz K.B. Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: analysis with zinc finger mutants and the progesterone antagonist ZK98299. Proc. Natl. Acad. Sci. U.S.A. 89 7 (1992) 3050-3054
19. Kastner P., Krust A., Turcotte B., Stropp U., Tora L., Gronemeyer H., and Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 9 5 (1990) 1603-1614
20. Tung L., Mohamed M.K., Hoeffler J.P., Takimoto G.S., and Horwitz K.B. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol. Endocrinol. 7 10 (1993) 1256-1265
21. Zhang X., Jeyakumar M., Petukhov S., and Bagchi M.K. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol. Endocrinol. 12 4 (1998) 513-524
22. Faivre E., Skildum A., Pierson-Mullany L., and Lange C.A. Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators. Steroids 70 5-7 (2005) 418-426
23. Skildum A., Faivre E., and Lange C.A. Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol. Endocrinol. 19 2 (2005) 327-339
24. Migliaccio A., Castoria G., Di Domenico M., de Falco A., Bilancio A., Lombardi M., Bottero D., Varricchio L., Nanayakkara M., Rotondi A., and Auricchio F. Sex steroid hormones act as growth factors. J. Steroid Biochem. Mol. Biol. 83 1-5 (2002) 31-35
25. Migliaccio A., Piccolo D., Castoria G., Di Domenico M., Bilancio A., Lombardi M., Gong W., Beato M., and Auricchio F. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 17 7 (1998) 2008-2018
26. Castoria G., Migliaccio A., Bilancio A., Di Domenico M., de Falco A., Lombardi M., Fiorentino R., Varricchio L., Barone M.V., and Auricchio F. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 20 21 (2001) 6050-6059
27. Castoria G., Barone M.V., Di Domenico M., Bilancio A., Ametrano D., Migliaccio A., and Auricchio F. Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J. 18 9 (1999) 2500-2510
28. Migliaccio A., Castoria G., Di Domenico M., De Falco A., Bilancio A., and Auricchio F. Src is an initial target of sex steroid hormone action. Ann. N. Y. Acad. Sci. 963 (2002) 185-190
29. Boonyaratanakornkit V., McGowan E., Sherman L., Mancini M.A., Cheskis B.J., and Edwards D.P. The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol. Endocrinol. 21 2 (2007) 359-375
30. Musgrove E.A., Lee C.S., Cornish A.L., Swarbrick A., and Sutherland R.L. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol. Endocrinol. 11 1 (1997) 54-66
31. McGowan E.M., Russell A.J., Boonyaratanakornkit V., Saunders D.N., Lehrbach G.M., Sergio C.M., Musgrove E.A., Edwards D.P., and Sutherland R.L. Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor. Cancer Res. 67 18 (2007) 8942-8951
32. Musgrove E.A., Lee C.S., and Sutherland R.L. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol. Cell Biol. 11 10 (1991) 5032-5043
33. Madauss K.P., Grygielko E.T., Deng S.J., Sulpizio A.C., Stanley T.B., Wu C., Short S.A., Thompson S.K., Stewart E.L., Laping N.J., Williams S.P., and Bray J.D. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol. Endocrinol. 21 5 (2007) 1066-1081
34. Heery D.M., Kalkhoven E., Hoare S., and Parker M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387 6634 (1997) 733-736
35. McInerney E.M., Rose D.W., Flynn S.E., Westin S., Mullen T.M., Krones A., Inostroza J., Torchia J., Nolte R.T., Assa-Munt N., Milburn M.V., Glass C.K., and Rosenfeld M.G. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev. 12 21 (1998) 3357-3368
36. Chen J.D., Umesono K., and Evans R.M. SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers. Proc. Natl. Acad. Sci. U.S.A. 93 15 (1996) 7567-7571
37. Perissi V., Staszewski L.M., McInerney E.M., Kurokawa R., Krones A., Rose D.W., Lambert M.H., Milburn M.V., Glass C.K., and Rosenfeld M.G. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev. 13 24 (1999) 3198-3208
38. Rosenfeld M.G., Lunyak V.V., and Glass C.K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 20 11 (2006) 1405-1428
39. Schulman I.G., Juguilon H., and Evans R.M. Activation and repression by nuclear hormone receptors: hormone modulates an equilibrium between active and repressive states. Mol. Cell Biol. 16 7 (1996) 3807-3813
40. Jackson T.A., Richer J.K., Bain D.L., Takimoto G.S., Tung L., and Horwitz K.B. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. 11 6 (1997) 693-705
41. Liu Z., Auboeuf D., Wong J., Chen J.D., Tsai S.Y., Tsai M.J., and O'Malley B.W. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc. Natl. Acad. Sci. U.S.A. 99 12 (2002) 7940-7944
42. Edwards D.P., Wardell S.E., and Boonyaratanakornkit V. Progesterone receptor interacting coregulatory proteins and cross talk with cell signaling pathways. J. Steroid Biochem. Mol. Biol. 83 1-5 (2002) 173-186
43. Tung L., Abdel-Hafiz H., Shen T., Harvell D.M., Nitao L.K., Richer J.K., Sartorius C.A., Takimoto G.S., and Horwitz K.B. Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Mol. Endocrinol. 20 11 (2006) 2656-2670
44. Boonyaratanakornkit V., Scott M.P., Ribon V., Sherman L., Anderson S.M., Maller J.L., Miller W.T., and Edwards D.P. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol. Cell 8 2 (2001) 269-280
45. Sartorius C.A., Tung L., Takimoto G.S., and Horwitz K.B. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J. Biol. Chem. 268 13 (1993) 9262-9266
46. Afhuppe W., Sommer A., Muller J., Schwede W., Fuhrmann U., and Moller C. Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system. J. Steroid Biochem. Mol. Biol. 113 1-2 (2009) 105-115